Vistagen initiated with an Outperform at William Blair

William Blair initiated coverage of Vistagen with an Outperform rating and $14 fair value estimate. The firm says VistaGen “remains an overlooked, undervalued name with differentiated assets in large mood disorder markets.” The analyst sees an asymmetric risk/reward profile at current shared levels based on Vistagens valuation.